Alternative transplant donor sources: is there any consensus?

Area of Science:

• Hematology
• Transplantation immunology
• Oncology

Background:

• Hematopoietic cell transplantation (HCT) is crucial for treating high-risk hematological malignancies.
• Finding a matched related donor is often challenging for many patients.
• Alternative donors offer a potential pathway for allogeneic transplantation.

Purpose of the Study:

• To review evidence supporting the use of alternative donors for HCT.
• To assess the efficacy and safety of alternative donor sources in patients with advanced hematological malignancies.

Main Methods:

• Review of available data and retrospective studies on alternative donor HCT.
• Analysis of advancements in supportive therapy and transplantation technologies.
• Evaluation of molecular matching techniques and novel therapeutic strategies.

Main Results:

• Improved safety and efficacy of alternative donors due to advances in supportive care and technology.
• Enhanced human leukocyte antigen (HLA) matching for unrelated donors.
• Promising outcomes with partially matched related donors using strategies like adoptive regulatory T cells or posttransplantation cyclophosphamide.
• Advancements in umbilical cord blood transplantation, including graft optimization and novel methodologies for accelerated engraftment.
• Retrospective studies indicate similar long-term outcomes across different alternative donor types despite variations in engraftment, graft-versus-host disease, and relapse rates.

Conclusions:

• Alternative donors are accessible for most patients lacking a matched related donor, enabling potentially curative allogeneic transplantation.
• Emerging technologies are poised to further enhance the safety and efficacy of alternative donor HCT.
• Future randomized studies are essential to precisely define the comparative effectiveness of various alternative donor sources.